Replies to post #81313 on Anavex Life Sciences Corp (AVXL)

[ven69]

I believe that was me on 11/19

https://www.insiderfinancial.com/anavex-life-sciences-corp-nasdaqavxl-and-biogen-inc-nasdaqbiib-a-perfect-match/

" Biogen needs Anavex more than Anavex needs Biogen. Biogen has a $68 billion market cap, yet its share price is only up 2% YTD. This follows a dismal 2015 where Biogen fired 11% of its workforce and enacted cost-cutting programs. Furthermore, Biogen has bet a great deal on Aducanumab for the treatment of Alzheimer’s. Aducanumab is part of the amyloid hypothesis that the plaques are responsible for the pathology of Alzheimer’s disease. However, the data from Aducanumab has been rather unimpressive. From this article on Seeking Alpha:"